in this issue
Pharma/fine chemicals roundup—29 January
9:27 AM MST | January 29, 2013 | By DEEPTI RAMESH
Lonza reports rises in profits and sales
Lonza recorded an 18.2% rise in net profits for 2012 compared with 2011, to 182 million Swiss francs ($196 million). Sales for 2012 increased 45.8%, to SF3.92 billion. Lonza says it achieved solid sales growth in 2012 with stable market demand, and following the Arch acquisition, revenues increased by 45.8%. Lonza’s technology toolbox attracted new customers in all areas and led to satisfactory capacity utilization at all sites. The volatile macroeconomic situation was challenging, but Lonza managed to balance most of the risks by delivering its product portfolio to a diverse set of markets, the company says. In early 2012 Lonza fired former CEO Stefan Borgas following weak financial results, and Richard Ridinger was appointed as the new CEO effective 1 May 2012.
Jörg Reinhardt to leave Bayer HealthCare
Bayer says that Jörg Reinhardt, 56, chairman of the board of management of Bayer HealthCare and a member of the Bayer executive council, will not renew his contract when it expires in summer 2013. Reinhardt has been chairman of the board of management of Bayer HealthCare since 15 August 2010. Wolfgang Plischke, 61, member of the Bayer management board, whose responsibilities currently include technology, innovation, and sustainability, will take over the function of chairman at Bayer HealthCare in addition to his existing duties until a successor is appointed.
Pfizer reports rise in profits, but Lipitor patent expiry impacts sales
Pfizer recorded a fourth-quarter 2012 net profits of $6.3 billion, compared with $1.4 billion in the prior-year quarter. Sales in the fourth quarter decreased 7%, however, to $15.1 billion. Full-year 2012 net profits were $14.6 billion, compared with $10 billion in 2011. Full-year 2012 sales were $59 billion, compared with $65.3 billion in 2011. Fourth-quarter and full-year 2012 earnings were favorably impacted partly by the gain on the sale of the nutrition business, Pfizer says.
For the full-year 2012, US sales were $23.1 billion, a decrease of 14% compared with 2011, primarily due to the loss of exclusivity of cholesterol-lowering drug Lipitor. Pfizer’s Lipitor has been the top-selling drug worldwide. Lipitor lost exclusivity in the United States in November 2011 and various other major markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenues by $5.6 billion in 2012, in comparison with 2011, Pfizer says. Pfizer’s international revenues in 2012 were $35.9 billion, a decrease of 6% compared with the prior year, mainly due to the losses of exclusivity of Lipitor and the unfavorable impact of foreign exchange.
Aoxing received license to produce pholcodine API
Aoxing Pharmaceutical (Shijiazhuang, China) says it has received a license from China’s State Food and Drug Administration (SFDA; Beijing) to produce the active pharmaceutical ingredient (API) in pholcodine. The company has begun preparation for the government's good manufacturing practices (GMP) inspection, which is the last regulatory hurdle before the company can take the product to market in China, Aoxing says.
“We currently have a number of other products that have completed clinical trials and are in the process of applying for the SFDA production license,” says Guirong Zhou, v.p./R&D at Aoxing. “Our success in obtaining a production license for the pholcodine API bodes well for success in our future applications.”
Eli Lilly reports fall in profits and sales
Eli Lilly reported a 4% fall in net profits in the fourth quarter of 2012, compared with the year-ago period, to $827.2 million. Fourth-quarter sales decreased 1%, to $5.95 billion. For the full-year 2012, net profits decreased 6%, compared with 2011, to $4.08 billion, and sales decreased 7%, to $22.6 billion.